Jennison Associates LLC Buys 8,837 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Jennison Associates LLC grew its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 5.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 158,187 shares of the company’s stock after acquiring an additional 8,837 shares during the period. Jennison Associates LLC owned 0.30% of Tyra Biosciences worth $3,719,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Tyra Biosciences by 18.6% in the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after purchasing an additional 140,833 shares during the last quarter. BVF Inc. IL increased its stake in shares of Tyra Biosciences by 70.1% in the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock valued at $76,444,000 after buying an additional 1,921,599 shares during the period. Kynam Capital Management LP raised its position in shares of Tyra Biosciences by 51.4% during the first quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after acquiring an additional 175,000 shares during the last quarter. RA Capital Management L.P. lifted its stake in shares of Tyra Biosciences by 43.9% during the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock valued at $170,832,000 after acquiring an additional 3,180,155 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Tyra Biosciences by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after acquiring an additional 14,352 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TYRA has been the subject of several recent research reports. HC Wainwright dropped their price objective on Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating for the company in a report on Monday, November 11th. Wedbush restated an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a report on Friday, October 25th. Piper Sandler began coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They set an “overweight” rating and a $33.00 target price for the company. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $22.00 to $31.00 in a research report on Friday, October 18th. Finally, Oppenheimer raised their price target on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $31.00.

Insider Buying and Selling at Tyra Biosciences

In other Tyra Biosciences news, CEO Todd Harris sold 19,084 shares of Tyra Biosciences stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $27.90, for a total value of $532,443.60. Following the transaction, the chief executive officer now owns 1,355,927 shares of the company’s stock, valued at approximately $37,830,363.30. The trade was a 1.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Nina S. Kjellson sold 27,493 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $16.56, for a total transaction of $455,284.08. Following the completion of the transaction, the director now owns 458,506 shares of the company’s stock, valued at $7,592,859.36. This trade represents a 5.66 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 101,050 shares of company stock valued at $2,235,492. Company insiders own 15.40% of the company’s stock.

Tyra Biosciences Price Performance

Tyra Biosciences stock opened at $15.83 on Friday. The firm has a market capitalization of $801.00 million, a price-to-earnings ratio of -9.76 and a beta of 1.08. The company’s 50 day simple moving average is $20.89 and its 200 day simple moving average is $19.89. Tyra Biosciences, Inc. has a fifty-two week low of $10.60 and a fifty-two week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.